{"id":"asf1057","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Limited public information is available on ASF1057's specific mechanism of action. As a Phase 3 asset from Astion Pharma, it is likely a targeted small molecule or biologic designed to modulate a specific disease pathway, but the exact molecular target and therapeutic mechanism require access to clinical trial data or company disclosures.","oneSentence":"ASF1057 is an investigational therapeutic targeting immune or inflammatory pathways in development by Astion Pharma.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:02:34.807Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[]},"trialDetails":[{"nctId":"NCT00565279","phase":"PHASE3","title":"Efficacy and Safety of ASF1057 in the Treatment of Seborrhoeic Dermatitis","status":"COMPLETED","sponsor":"Astion Pharma A/S","startDate":"2007-12","conditions":"Seborrheic Dermatitis","enrollment":300}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"ASF1057","genericName":"ASF1057","companyName":"Astion Pharma A/S","companyId":"astion-pharma-a-s","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}